News for BRAIN Biotech AG (BNN.DE)

Akribion Therapeutics, a Zwingenberg-based BioTech startup developing a RNA-guided, nuclease-based technology for programmable cell depletion, today

Earnings call: Royalty Pharma reports robust Q3 growth, raises guidance

Portfolio Receipts growth of 15% to $735 million; Royalty Receipts growth of 15%Net cash provided by operating activities of $704 millionCapital Deployment...

EQS-Ad-hoc: BRAIN Biotech AG / Key word: Bond BRAIN Biotech AG: Issuance of EUR 5 million convertible bond with exclusion of subscription rights 29-Feb-2024 / 20:06 CET/CEST Disclosure of...

EQS-News: BRAIN Biotech AG / Key word: Quarterly / Interim Statement 3M FY 23/24:  BRAIN Biotech looks optimistic to stay on the growth path for fiscal year 2023/24...

EQS Preliminary announcement financial reports: BRAIN Biotech AG / Preliminary announcement on the disclosure of financial statements BRAIN Biotech AG: Preliminary announcement...

The global Food Enzymes market size is expected to reach USD 2.59 billion by 2030 and exhibit a CAGR of 4.80% in the forecast period (2023−2030), according...

EQS-News: BRAIN Biotech AG / Key word: Miscellaneous Akribion Genomics receives the Hessian Founder Award for its innovative approach to a new cancer therapy 20.11.2023 /...

EQS-News: BRAIN Biotech AG / Key word: Patent BRAIN Biotech AG: BRAIN Biotech AG’s Akribion Genomics technology receives patent approval for its groundbreaking...

EQS-News: BRAIN Biotech AG / Key word(s): Miscellaneous BRAIN Biotech AG´s Akribion Genomics team successfully competes in Science4Life Venture Cup competition 28.06.2023 / 13:00 CET/CEST The issuer is sol...